What Next - The Odyssey’s Neverending Journey Through the Discourse
Roiling like a wine-dark sea since the casting was announced, controversies surrounding Christopher Nolan’s “The Odyssey” didn’t stop with the film’s release. But what turned a summer blockbuster into...
3 Aug 27min
Amicus With Dahlia Lithwick | Law, justice, and the courts - By The People | Two Steps Forward, One Step Back
Long before the Supreme Court handed down the landmark Obergefell ruling on equal marriage in 2015, activists were canvassing door-to-door, courting any lawmaker who would listen, and losing at the lo...
1 Aug 45min
ICYMI - Women's Health Is Not Your Clickbait
Women’s health is being yassified online, from ill-advised marketing campaigns by companies trying to go viral to creators pushing anti-abortion agendas under the guise of “natural” birth control. It ...
1 Aug 39min
Slate Money - Too Situationally Aware to Fail
This week: Situational Awareness—an A.I.-forward hedge fund led by a former wunderkind and OpenAI employee—was tanking fast until a rival fund stepped in. Felix Salmon, Elizabeth Spiers, and Emily Pec...
1 Aug 54min
What Next - Bonus: Cory Booker on Blanche, Epstein, and 2028
As part of the Senate Judiciary Committee, Senator Cory Booker had questions for Todd Blanche—and made space for Jeffrey Epstein survivors. Guest: Cory Booker, US Senator for New Jersey, member of the...
31 Jul 6min
What Next: TBD | Tech, power, and the future - Can We Trust the Jobs Report?
The Bureau of Labor Statistics is a department for wonks, by wonks. But under the dual pressures of the changing nature of work—like the growing gig economy—and an administration that doesn’t accept b...
31 Jul 32min
Political Gabfest - Unhinged Obsession
This week, Emily Bazelon, John Dickerson, and David Plotz discuss the expanding Iran war and what it means for Trump that news of U.S. missile shortages is leaking from the inside, the blend of conspi...
30 Jul 50min
What Next - What the Hell is a Peptide?
On the heels of the success of GLP-1s like Ozempic, other peptide treatments are flooding the marketplace—and advertising spaces. But even as the Trump administration’s FDA discusses approving more tr...
30 Jul 26min
